Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APREOTCMKTS:BPMUFNASDAQ:PRVBNASDAQ:RAPTNASDAQ:TRIL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$5.07-5.6%$6.43$2.78▼$8.85$27.53M1.0329,568 shs5,658 shsBPMUFBasilea Pharmaceutica$44.45$41.34$38.60▼$44.45$526.73M0.655 shsN/APRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsRAPTRAPT Therapeutics$7.90-1.3%$9.94$6.86▼$27.35$274.92M0.471.16 million shs191,790 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+4.07%-5.79%-12.25%-4.62%+37.40%BPMUFBasilea Pharmaceutica0.00%0.00%+9.08%+15.16%-14.52%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.38%RAPTRAPT Therapeutics+1.78%-1.60%-3.96%-65.35%-57.33%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.389 of 5 stars3.55.00.00.02.23.30.6BPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics4.4344 of 5 stars4.34.00.03.62.01.70.6TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics3.00Buy$15.50205.72% UpsideBPMUFBasilea PharmaceuticaN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/ARAPTRAPT Therapeutics2.50Moderate Buy$25.67224.89% UpsideTRILTrillium TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TRIL, BPMUF, PRVB, APRE, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.002/21/2024RAPTRAPT TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $15.002/21/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/20/2024RAPTRAPT TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K47.47N/AN/A$4.54 per share1.12BPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RAPTRAPT Therapeutics$1.53M179.69N/AN/A$4.27 per share1.85TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)BPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ALatest TRIL, BPMUF, PRVB, APRE, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APREAprea Therapeutics-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.135.13BPMUFBasilea PharmaceuticaN/A3.202.64PRVBProvention Bio0.191.931.92RAPTRAPT TherapeuticsN/A7.417.41TRILTrillium TherapeuticsN/A19.8219.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%BPMUFBasilea PharmaceuticaN/APRVBProvention Bio37.39%RAPTRAPT Therapeutics99.09%TRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics20.90%BPMUFBasilea PharmaceuticaN/APRVBProvention Bio13.10%RAPTRAPT Therapeutics6.60%TRILTrillium Therapeutics9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.43 million4.30 millionNo DataBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableTRIL, BPMUF, PRVB, APRE, and RAPT HeadlinesSourceHeadlineCachet Bicycle shakes off COVIDbaytoday.ca - February 25 at 12:23 PMRejuvenate your look with a trip to Fourth Avenue Medical Aestheticschch.com - January 30 at 5:32 PMTTI apprehends motorists for illegal removal of clamps, hunt for four others underwaybulawayo24.com - January 30 at 5:32 PMBridgeBio raises $1.25bn, and other biotech financingspharmaphorum.com - January 19 at 7:18 AMRatio Therapeutics Raises $50M in Series B Financingprecisionmedicineonline.com - January 17 at 1:39 PMLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.combusinesswire.com - November 10 at 1:22 PMMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 8 at 1:30 AMThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast perioduk.finance.yahoo.com - July 31 at 9:03 AMRatio Therapeutics unveils new research and development facilitybiopharma-reporter.com - May 15 at 10:33 AMWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'msn.com - April 26 at 12:18 AMLeukemia Therapeutics Global Market Report 2023uk.finance.yahoo.com - April 4 at 10:35 AMRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merckfinance.yahoo.com - March 28 at 9:12 AMTrillium House, an affordable housing project in Warrenton, close to completiondailyastorian.com - January 10 at 12:26 AMFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinomanz.finance.yahoo.com - October 19 at 9:39 AMCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatmentseekingalpha.com - September 14 at 9:48 AMZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directorsnz.finance.yahoo.com - September 12 at 7:55 AMPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Neededseekingalpha.com - August 17 at 11:07 AMTTI reviews parking modelchronicle.co.zw - August 10 at 10:41 PMTTI working round the clock to configure its systemschronicle.co.zw - August 10 at 10:41 PMPfizer in advanced talks to buy firm making sickle cell drugspmnewsnigeria.com - August 7 at 3:57 AM10 Psychedelics CEOs To Pay Attention To In 2022markets.businessinsider.com - June 22 at 10:08 AMHighlights from ASCO Annual Meeting 2022healio.com - June 15 at 1:37 PMChlormethine gel may be more effective than ointment for mycosis fungoideshealio.com - May 27 at 4:34 PMPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?edition.cnn.com - May 20 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Basilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyTrillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.